Checklist guides
Structured prompts help readers assess what is known, what is not known, what safety questions remain, and what would need independent verification before treating a claim as meaningful.
Independent information resource
Services
Guides, comparisons, and research summaries for examining ibogaine-related claims in multiple sclerosis with clear uncertainty and safety in view.
A checklist is a way to slow down.
Multiple sclerosis is a chronic disease of the central nervous system, and established care is not interchangeable with a claim about an unproven substance. The ibogaine and MS checklist overview frames the questions that should come before a conclusion.
What we provide
Information built for difficult questions.
Wide Anchor 57 is an independent resource for evaluating ibogaine research in multiple sclerosis. Our approach and editorial principles explain how we separate limited evidence, substantial risks, and unanswered questions from claims that can sound more certain than the evidence allows.
For basic clinical context, the National Institute of Neurological Disorders and Stroke describes multiple sclerosis as a condition affecting the central nervous system. That context matters when reviewing any proposed intervention.
Evidence summaries
We map the difference between a research hypothesis and established MS care, including why claims about ibogaine itself should not be mistaken for evidence of benefit in multiple sclerosis.
Comparisons and context
Readers can compare common discussion points across related topics, including questions about ibogaine treatment costs in Mexico and the practical difference between a treatment claim and a reliable evidence base.
Plain-language reference notes
Short explainers clarify terms, legal uncertainty, and common framing. A discussion of whether ibogaine is illegal can help identify why legal status is separate from questions about efficacy or medical safety.
A review framework
Questions that remain visible.
A useful review does not collapse separate issues into one promise. Information about ibogaine clinics may be relevant to how a service is presented, but it cannot establish that an intervention is appropriate for MS.
- Is there direct evidence in people with multiple sclerosis, rather than an analogy from another condition?
- Are potential harms and contraindications described as clearly as possible benefits?
- Does the claim distinguish personal accounts from controlled clinical evidence?
Clear uncertainty
The gap between interest and evidence matters.
“A compelling story is not the same thing as an established treatment pathway.”
Our comparative notes include adjacent searches for ibogaine treatment for depression and information associated with ibogaine for depression, because a claim in one setting does not answer the MS-specific questions.
We also flag safety language around reported ibogaine aftereffects. People considering health decisions should discuss individual circumstances with appropriately qualified healthcare professionals rather than treating a general guide as medical advice.
Frequently asked questions
Use the resource as a starting point, not a verdict.
Does this resource provide ibogaine treatment?
No. Wide Anchor 57 is an independent information resource. It does not provide medical care, recommend treatment, or operate as a clinic or licensed treatment center.
Why include information about addiction treatment?
Searches for ibogaine for addiction treatment can shape expectations about the substance. Context may be useful, but it should not be used to infer evidence for multiple sclerosis.
What is the role of established MS care?
Established care should remain distinct from an unproven claim. The National MS Society’s overview of MS provides general background on the condition and reinforces why a condition-specific assessment is essential.
Continue with context
Careful reading is part of the checklist.
Explore the evidence summary, safety checklist, and research roadmap to keep the central questions in view: what is known, what remains uncertain, and where risks may be understated.
View the evidence summary